TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+0.75%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.44B
AUM Growth
+$2.44B
(-4%)
Cap. Flow
-$52.5M
Cap. Flow
% of AUM
-2.15%
Top 10 Holdings %
Top 10 Hldgs %
38.65%
Holding
187
New
10
Increased
35
Reduced
38
Closed
19
Top Buys
| 1 |
Johnson & Johnson
JNJ
|
$43.6M |
| 2 |
Humana
HUM
|
$23.9M |
| 3 |
Eli Lilly
LLY
|
$20.7M |
| 4 |
Illumina
ILMN
|
$18.9M |
| 5 |
Abbott
ABT
|
$15.8M |
Top Sells
| 1 |
McKesson
MCK
|
$43.2M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$23.3M |
| 3 |
UnitedHealth
UNH
|
$23M |
| 4 |
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
|
$21.7M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$19.4M |
Sector Composition
| 1 | Healthcare | 96.9% |
| 2 | Real Estate | 1.86% |
| 3 | Industrials | 0.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Zimmer Biomet
ZBH
$21B
| $27.1M | 1.11% | 258,868 +116,824 | +82% | +$12.2M |
|
27
argenx
ARGX
$43.6B
| $27.1M | 1.11% | 76,635 +38,179 | +99% | +$13.5M |
|
28
Medtronic
MDT
$119B
| $26.3M | 1.08% | 326,172 | – | – |
|
29
Rallybio
RLYB
$22.4M
| $25.2M | 1.03% | 1,740,931 -190,189 | -10% | -$2.75M |
|
30
United Therapeutics
UTHR
$13.8B
| $24.6M | 1.01% | 117,377 +45,171 | +63% | +$9.46M |
|
31
Jazz Pharmaceuticals
JAZZ
$7.75B
| $24.4M | 1% | 182,782 +14,883 | +9% | +$1.98M |
|
32
HCA Healthcare
HCA
$94.5B
| $22.8M | 0.94% | 124,303 | – | – |
|
33
Zoetis
ZTS
$69.3B
| $20.3M | 0.83% | 136,914 -9,800 | -7% | -$1.45M |
|
34
DexCom
DXCM
$29.5B
| $19.8M | 0.81% | 245,712 +115,828 | +89% | +$9.33M |
|
35
Intuitive Surgical
ISRG
$170B
| $19.6M | 0.8% | 104,403 -1,773 | -2% | -$332K |
|
36
Guardant Health
GH
$8.41B
| $18.6M | 0.76% | 346,084 -5,400 | -2% | -$291K |
|
37
Sarepta Therapeutics
SRPT
$1.78B
| $18.3M | 0.75% | 165,959 -46,206 | -22% | -$5.11M |
|
38
Apellis Pharmaceuticals
APLS
$3.48B
| $18.2M | 0.74% | 266,076 -46,116 | -15% | -$3.15M |
|
39
Neurocrine Biosciences
NBIX
$13.8B
| $17.9M | 0.73% | 168,108 | – | – |
|
40
Idexx Laboratories
IDXX
$51.8B
| $17.7M | 0.72% | 54,207 +1,297 | +2% | +$423K |
|
41
Lantheus
LNTH
$3.73B
| $16.1M | 0.66% | 229,179 +102,087 | +80% | +$7.18M |
|
42
Charles River Laboratories
CRL
$8.04B
| $14.3M | 0.59% | 72,675 +24,781 | +52% | +$4.88M |
|
43
Edwards Lifesciences
EW
$47.8B
| $14.2M | 0.58% | 171,388 | – | – |
|
44
ResMed
RMD
$40.2B
| $13.3M | 0.54% | 60,699 -10,300 | -15% | -$2.25M |
|
45
Novo Nordisk
NVO
$251B
| $13M | 0.53% | 130,523 | – | – |
|
46
BioNTech
BNTX
$24B
| $12.8M | 0.52% | 95,042 | – | – |
|
47
BioMarin Pharmaceuticals
BMRN
$11.2B
| $12.8M | 0.52% | 150,947 +22,943 | +18% | +$1.94M |
|
48
IQVIA
IQV
$32.4B
| $12.3M | 0.5% | 67,817 -16,486 | -20% | -$2.99M |
|
49
CVS Health
CVS
$92.8B
| $11.8M | 0.48% | 123,803 | – | – |
|
50
SPDR S&P Biotech ETF
XBI
$5.07B
| $11.7M | 0.48% | 147,677 -61,477 | -29% | -$4.88M |
|